Biliary Tract Cancer near Yorktown Heights, NY

Biography: Dr. Hua-Jay "Jeff" Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. His research on ctDNA in patients with relapsed lymphoma receiving chimeric antigen receptor T-cell therapy is funded by a Conquer Cancer Young Investigator Award grant. He is a member of Southwestern Oncology Group Lymphoma Working Group and Committee. He was selected to participate in the Academy of Next Wave of Investigators for non-Hodgkin's lymphoma and the American Society of Hematology Clinical Research Training Institute, competitive programs aimed at supporting academic and career development for promising clinical researchers. Dr. Cherng's goal is to design clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.

Biography: Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow. Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Biography: Andrew Eisenberger graduated from Columbia University with a BA in Philosophy in 1992 and received his MD from Albert Einstein College of Medicine in 2001. Dr. Eisenberger did his residency in internal medicine at Montefiore Medical Center, where he served for a year as chief resident. He then completed his fellowship in Hematology/Oncology at New York Presbyterian Hospital/Columbia University Medical Center. Dr. Eisenberger embraces his role as a medical educator: for medical students, physicians in training, colleagues and patients alike. The Columbia University Vagelos School of Physicians and Surgeons' Hematology course has been under his leadership for more than a decade, and he recently became an associate program director of the University's Hematology/Oncology post-doctoral fellowship program. Dr. Eisenberger was inducted into the Medical Center's Academy of Clinic Excellence in 2018. His clinical practice currently focuses on the diagnosis and management of complex bleeding and clotting disorders, particularly in unique populations such as pregnant women and critically ill hospitalized patients. He also has extensive experience with difficult-to-manage blood disorders including antiphospholipid antibody syndrome (APLS), heparin-induced thrombocytopenia (HIT), immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), thrombotic thrombocytopenic purpura (TTP), hematologic complications of solid organ transplantation and myeloproliferative neoplasms.